Company: MDCXW
Filing Date: 2025-06-23
Form Type: PRER14A
Source: 0001062993-25-012067
Chunk: 91

Company: Medicus Pharma Ltd.
Filing Date: 2025-06-23
Form: PRER14A
Chunk 91
---
 and reports as the Committee may deem appropriate in order to fulfill its duties.

4.DUTIES AND RESPONSIBILITIES

The duties and responsibilities of the Committee as they relate to the following matters, to the extent considered appropriate or desirable or required by Applicable Laws, are to:

4.1.Financial Reporting and Disclosure

(i)review and discuss with the Auditor and management of the Company and, upon satisfactory completion of its review, recommend to the Board for approval, the audited annual financial statements and note disclosure of the Company, including the auditors' report thereon, the management's discussion and analysis of the Company prepared in connection with the annual financial statements, financial reports of the Company, guidance with respect to earnings per share, and any initial public release of financial information of the Company through press release or otherwise, with such documents to indicate whether such information has been reviewed by the Board or the Committee;

(ii)review with the Company's management and, if applicable, the Auditor and recommend to the Board for approval, the quarterly financial statements of the Company including the management's discussion and analysis prepared in connection with the quarterly financial statements, with such documents to indicate whether such information has been reviewed by the Board or the Committee;

(iii)review and recommend to the Board for approval, where appropriate, financial information contained in any prospectuses, annual information forms, annual reports to shareholders, management proxy circulars, press releases, material change disclosures of a financial nature and similar disclosure documents;

<div align='center'>SC C-2</div>

(iv)review with management of the Company and with the Auditor and assess significant accounting principles and disclosure issues and alternative treatments under International Financial Reporting Standards ("IFRS") or generally accepted accounting principles in the United States ("U.S. GAAP"), as applicable, all with a view to gaining reasonable assurance that financial statements present fairly, in all material respects, the Company's financial position, cash flows and the results of its operations in accordance with IFRS or U.S. GAAP, as applicable;

(v)annually review the Company's corporate disclosure policy and recommend any proposed changes to the Board for consideration; and

(vi)review the minutes from each meeting of the disclosure committee of the Company established pursuant to the Company's corporate disclosure policy, since the last meeting of the Committee.

4.2.Internal Controls and Audit

(i)review and assess the adequacy and effectiveness of the Company's system of internal control and management information systems through discussions with management of the Company and the Auditor to ensure